University of Ghana School of Medicine and Dentistry, Accra, Ghana.
Korle-Bu Teaching Hospital, Accra, Ghana.
BMC Infect Dis. 2018 Apr 2;18(1):149. doi: 10.1186/s12879-018-3053-5.
Mycobacterium tuberculosis drug resistance is a major challenge to the use of standardized regimens for tuberculosis (TB) therapy, especially among previously treated patients. We aimed to investigate the frequency and pattern of drug resistance among previously treated patients with smear-positive pulmonary tuberculosis at the Korle-Bu Teaching Hospital Chest Clinic, Accra.
This was a cross-sectional survey of mycobacterial isolates from previously treated patients referred to the Chest Clinic Laboratory between October 2010 and October 2013. The Bactec MGIT 960 system for mycobactrerial culture and drug sensitivity testing (DST) was used for sputum culture of AFB smear-positive patients with relapse, treatment failure, failure of smear conversion, or default. Descriptive statistics were used to summarize patient characteristics, and frequency and patterns of drug resistance.
A total of 112 isolates were studied out of 155 from previously treated patients. Twenty contaminated (12.9%) and 23 non-viable isolates (14.8%) were excluded. Of the 112 studied isolates, 53 (47.3%) were pan-sensitive to all first-line drugs tested Any resistance (mono and poly resistance) to isoniazid was found in 44 isolates (39.3%) and any resistance to streptomycin in 43 (38.4%). Thirty-one (27.7%) were MDR-TB. Eleven (35.5%) out of 31 MDR-TB isolates were pre-XDR. MDR-TB isolates were more likely than non-MDR isolates to have streptomycin and ethambutol resistance.
The main findings of this study were the high prevalence of MDR-TB and streptomycin resistance among previously treated TB patients, as well as a high prevalence of pre-XDR-TB among the MDR-TB patients, which suggest that first-line and second-line DST is essential to aid the design of effective regimens for these groups of patients in Ghana.
结核分枝杆菌耐药性是标准化结核(TB)治疗方案应用的主要挑战,尤其是在既往治疗过的患者中。我们旨在研究加纳科勒布教学医院胸科诊所既往治疗过的涂片阳性肺结核患者中耐药的频率和模式。
这是一项对 2010 年 10 月至 2013 年 10 月期间转诊至胸科诊所实验室的既往治疗过的患者分枝杆菌分离株的横断面调查。Bactec MGIT 960 系统用于培养分枝杆菌和药物敏感性试验(DST),对复发、治疗失败、痰涂片未转化或失访的 AFB 涂片阳性患者进行痰培养。采用描述性统计方法总结患者特征、耐药的频率和模式。
共研究了 155 例既往治疗过的患者中的 112 例分离株。排除了 20 例污染(12.9%)和 23 例非存活分离株(14.8%)。在所研究的 112 例分离株中,53 株(47.3%)对所有测试的一线药物均敏感。44 株(39.3%)异烟肼耐药,43 株(38.4%)链霉素耐药。31 株(27.7%)为 MDR-TB。31 例 MDR-TB 分离株中有 11 例(35.5%)为预 XDR-TB。MDR-TB 分离株比非 MDR 分离株更有可能对链霉素和乙胺丁醇耐药。
本研究的主要发现是既往治疗过的 TB 患者中 MDR-TB 和链霉素耐药率较高,以及 MDR-TB 患者中预 XDR-TB 发生率较高,这表明一线和二线 DST 对于为加纳这些患者群体设计有效的治疗方案至关重要。